May 31, 2017 12:23 pm UTC| Business
Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland, May 31, 2017 - Auris...
May 31, 2017 12:23 pm UTC| Business
Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland, May 31, 2017 - Auris...
May 31, 2017 12:23 pm UTC| Business
Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland, May 31, 2017 - Auris...
May 31, 2017 12:23 pm UTC| Business
Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland, May 31, 2017 - Auris...
May 31, 2017 12:23 pm UTC| Business
Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland, May 31, 2017 - Auris...
May 31, 2017 12:23 pm UTC| Business
Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland, May 31, 2017 - Auris...
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
May 31, 2017 12:22 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., May 31, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...
US–India Trade Turbocharge: Stocks Poised to Ride the Export Wave